Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Comparison of High-Flux, Super High-Flux, Medium Cut-Off Hemodialysis and Online Hemodiafiltration on the Removal of Uremic T
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of High-Flux, Super High-Flux, Medium Cut-Off Hemodialysis and Online Hemodiafiltration on the Removal of Uremic Toxins
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of Hospitalization Rate in Automatized Peritoneal Dialysis Patients with and Without Remote Management Program in Colombia - Rivera A et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of medium cut-off membrane and postdilution hemodiafiltration on removal of small and middle molecule uremic toxins
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of Solute Removal Properties Between High-Efficient Dialysis Modalities in Low Blood Flow Rate
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of the medium cutoff dialyzer and postdilution hemodiafiltration on the removal of small and middle molecule uremic toxins
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Comparison of Utilities Consumption Between Different Modalities of In-Center Haemodialysis
Visit resource site
PD
Cost Consequence Analysis of a Remote Monitoring Program to Improve Clinical Practice of Automatized Peritoneal Dialysis in Colombia - Ariza J et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Current approaches to middle molecule removal: room for innovation
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Determining factors for hemodiafiltration to equal or exceed the performance of expanded hemodialysis.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Differences in drug removal between standard high-flux and medium cut-off dialyzers in a case of severe vancomycin toxicity.
Visit resource site
PD
Discrepancy between prescribed and actual APD prescription delivery: Identification using cycler remote management technology - Firanek CA, et al.
Download PDF

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.